Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects

The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin

(2014) Rakesh K. Pathak et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells

(2014) Qinqin Cheng et al.   CHEMICAL COMMUNICATIONS

Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery

(2014) Yao-Rong Zheng et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Crystal structure of the human glucose transporter GLUT1

(2014) Dong Deng et al.   NATURE

Highly water-soluble platinum(ii) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties

(2013) Pengxing Liu et al.   CHEMICAL COMMUNICATIONS

Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity

(2013) William D. Figg et al.   Clinical Genitourinary Cancer

What do we know about the reduction of Pt(IV) pro-drugs?

(2012) Ezequiel Wexselblatt et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells

(2011) Murugan Kalimutho et al.   ACTA PHARMACOLOGICA SINICA

Drug transporters of platinum-based anticancer agents and their clinical significance

(2011) Herman Burger et al.   DRUG RESISTANCE UPDATES

Clinical and pharmacokinetic evaluation of satraplatin

(2011) Gury Doshi et al.   Expert Opinion on Drug Metabolism & Toxicology

Pt(IV) complexes as prodrugs for cisplatin

(2011) Yi Shi et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer

(2011) Jeremy Cetnar et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

(2010) Elisa Gallerani et al.   ACTA ONCOLOGICA

Different Features of the DNA Binding Mode of Antitumorcis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) and Cisplatin in Vitro

(2010) Hana Kostrhunova et al.   CHEMICAL RESEARCH IN TOXICOLOGY

The status of platinum anticancer drugs in the clinic and in clinical trials

(2010) Nial J. Wheate et al.   DALTON TRANSACTIONS

Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes

(2010) Michael R. Reithofer et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Mechanisms of Cisplatin Nephrotoxicity

(2010) Ronald P. Miller et al.   Toxins

Satraplatin: leading the new generation of oral platinum agents

(2009) Ashish Bhargava et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

(2008) H. Choy et al.   CLINICAL CANCER RESEARCH

Tumor Cell Metabolism Imaging

(2008) C. Plathow et al.   JOURNAL OF NUCLEAR MEDICINE

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

(2008) S. Dhar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA